October 20, 2016 08:59 AM EDT

Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round

Arch Venture Partners has fostered a new neurosciences biotech company that will now follow a similar trail to the one being blazed by the high …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by neu­ro en­thu­si­ast Arch, up­start Black­Thorn tack­les some tough tar­gets with $40M round